Three drugs, each of which works in a different way, are used in anti-platelet therapy to help prevent restenosis (the reclogging of blood vessels after they have been cleared with percutaneous coronary intervention or PCI) or thrombosis (obstruction of an artery or vein by a blood clot). The use of these platelet inhibitory drugs -- cilostazol, clopidogrel and aspirin -- has resulted in a significant reduction of thrombotic complications in the primary and secondary prevention of heart attacks. But is it safe to use these medications together -- or in combination do they increase the risk of bleeding? And will patients comply with taking three pills?
In a poster session presented today at the American College of Cardiologys 54th Scientific Sessions in Orlando, Florida, Emory researchers say the answer to both questions is "yes".
The scientists analyzed data from the Cilostazol for RESTenosis (CREST) Trial, a randomized clinical trial testing the efficacy of cilostazol to prevent restenosis after PCI. Earlier results from CREST showed a 35% relative risk reduction in restenosis from 34% to 22% with cilostazol. The anti-thrombotic drugs Clopidogrel (75 mg daily for 30 days) and aspirin daily for 6 months were administered to all patients in the CREST trial while a total of 705 of these patients were randomized to cilostazol (354) or placebo (351) following successful angioplasty and stent implantation.
Sherry Baker | EurekAlert!
Antibiotic effective against drug-resistant bacteria in pediatric skin infections
17.02.2017 | University of California - San Diego
Tiny magnetic implant offers new drug delivery method
14.02.2017 | University of British Columbia
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
17.02.2017 | Medical Engineering
17.02.2017 | Medical Engineering
17.02.2017 | Health and Medicine